The following information is presented for educational purposes only. Medical Marijuana Inc. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred.
Real Scientific Hemp Oil-X™ (RSHO™) was the focus of a groundbreaking new study for patients with Lennox-Gastaut Syndrome, conducted by pediatric neurologist Dr. Saul Garza Morales. The study, announced at a press conference today, takes a direct look at the use of THC-free RSHO-X™ by patients suffering from Lennox-Gastaut Syndrome and measures the results they saw.
The results of the study revealed a significant reduction in the frequency of seizures for patients with Lennox-Gastaut. A 50 percent or greater reduction in seizures was obtained in 33 out of 39 or 84 percent of the cases, while 53 percent of the cases achieved an overall reduction in seizure activity of over 75 percent. A complete elimination of seizures for at least 4 months was achieved in 7 cases (17 percent of the patients), which the study characterizes as an outstanding result for this type of patient. The seizures that responded best from the use of pure CBD were atonic, absent, and generalized tonic, reaching a reduction of 30 to 100 percent.
“The results of this study are very exciting as they show the best results of any product/medication ever recorded regarding the reduction of seizures in Lennox-Gastaut Syndrome patients, with 17% of patients in the study experiencing 100 percent relief from their seizures,” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “Studies that prove the therapeutic benefits of CBD are vital, as they will continue to help fuel less restrictive medical cannabis programs not only in Mexico, but across the globe. This is such encouraging news that children with such a severe form of epilepsy now have an option for relief as opposed to a prior bleak diagnosis that offered no signs of beneficial treatment, once the epilepsy moves to the refractory (drug resistant) phase.”
Other benefits were recorded in 89 percent of patients, including increased alertness in 43 percent of patients, improved social interaction in 40 percent, and increased attention in 30 percent. To help verify observed results, all patients had imaging studies (CT or MRI) and at least two EEG studies, giving Dr. Garza brain imaging data to examine alongside observable changes and seizure numbers. Most importantly, zero percent of the participants in the study experienced serious adverse effects.
From January of 2016 to February of 2017, 45 patients diagnosed with Lennox-Gastaut Syndrome, a neurological disorder causing seizures that is diagnosed in young children, were studied by Dr. Saul Garza Morales, a highly respected pediatric neurologist based in Mexico. The patients enrolled in the study experienced a persistence of various types of seizures per day, despite taking at least three anti-epileptic drugs. Some patients removed themselves from the research for various reasons, leaving 39 cases at the end of the study. These patients took RSHO-X™ pure CBD oil in progressive doses of up to 5-7 mg of CBD per kg of body weight for at least 6 months after the study began.
Lennox-Gastaut is a type of severe epilepsy that develops during early childhood and is characterized by a high volume of seizures. The syndrome typically causes impaired intellectual development and limits information processing. The type of seizures caused by Lennox-Gastaut syndrome can include tonic (body stiffens, eyes deviate upward, pupils dilate, respiratory patterns become altered), atonic (brief loss of consciousness and muscle tone, abrupt falling), atypical absence (spell of staring), and myoclonic (sudden muscle jerks). The Epilepsy Foundation, however, notes that tonic and atonic seizures are most common in Lennox-Gastaut syndrome.
The study concludes, “Additional treatment with 100% Cannabidiol is a good alternative for patients with LGS and reduces the use and potential effects of tetrahydrocannabinol (THC).”
The study was undertaken in Mexico, where Medical Marijuana, Inc. subsidiary HempMeds® Mexico provides RSHO-X™ as a prescription medication. According to Raul Elizalde, “This study represents an important landmark in the history of Mexican medicine, since it is the first scientific evidence in our country about the positive effect of products such as RSHO-X™ in the treatment of patients with epilepsy who have not found improvement with conventional treatments”.
These conclusions are a marked improvement from the results achieved in a study featuring Epidiolex. In a study by Dr. Orrin Devinsky using Epidiolex, a CBD-based prescription medication currently in clinical trials in the U.S., for Lennox-Gastaut and Dravet Syndrome patients, another form of severe epilepsy, results proved to be less promising than those seen with RSHO-X™.
“Dr Garza’s study is a huge victory for botanical CBD as opposed to the pharmaceutically developed alternative,” continued Dr. Titus. “We fully believe in the entourage effect of the natural botanical product – both in terms of safety as well as efficacy.”
Although patients took higher doses of CBD from Epidiolex than RSHO-X™, they saw nearly half the reduction of seizures and no patient saw a reduction in seizures of over 50 percent. Epidiolex patients also recorded no quality of life improvements, and 30 percent experienced adverse effects. Based on these results, Dr. Garza Morales’s study reported a much better treatment of Lennox-Gastaut symptoms with RSHO-X™ than Dr. Devinsky’s study using Epidiolex.
In discussing his study, Dr. Garza Morales remarked, “We hope this study encourages both public health institutions and other health professionals to offer a new therapeutic solution that will help thousands of children with neurodegenerative diseases. For the first time in Mexican history, we did a scientific study that confirms the benefits of cannabidiol.”
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.